Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 pilot study of ARC1779 in von Willebrand factor-related platelet function disorders
ISRCTN28462186Phase 2Completed
- Sponsor
- Archemix Corp.
- Start
- Jan 2008
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of egaptivon pegol in thrombotic thrombocytopenic purpura (TTP) and von Willebrand disease type 2B (VWD2B) (7 arms), sponsored by Archemix Corp. Primary endpoint: Overall safety and tolerability of ARC1779. Started Jan 2008; status: completed.
02
Drugs
egaptivon pegol
03
Conditions
thrombotic thrombocytopenic purpura (TTP)von Willebrand disease type 2B (VWD2B)
Beyond the preview
Go deeper on ISRCTN28462186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN28462186.